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Abstract: Patients with chronic kidney disease (CKD), including those with end-stage renal dis-
ease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular 
disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, 
is an important risk factor for CVD development. Specific quantitative and qualitative changes 
are seen at different stages of renal impairment and are associated with the degree of glomeru-
lar filtration rate declining. Patients with non-dialysis-dependent CKD have low high-density 
lipoproteins (HDL), normal or low total cholesterol (TC) and low-density lipoprotein (LDL) 
cholesterol, increased triglycerides as well as increased apolipoprotein B (apoB), lipoprotein(a) 
(Lp (a)), intermediate- and very-low-density lipoprotein (IDL, VLDL; “remnant particles”), and 
small dense LDL particles. In patients with nephrotic syndrome lipid profile is more athero-
genic with increased TC, LDL, and triglycerides. Lipid profile in hemodialysis (HD) patients is 
usually similar to that in non-dialysis-dependent CKD patients. Patients on peritoneal dialysis 
(PD) have more altered dyslipidemia compared to HD patients, which is more atherogenic in 
nature. These differences may be attributed to PD per se but may also be associated with the 
selection of dialytic modality. In renal transplant recipients, TC, LDL, VLDL, and triglycerides 
are elevated, whereas HDL is significantly reduced. Many factors can influence post-transplant 
dyslipidemia including immunosuppressive agents. This patient population is obviously at high 
risk; hence, prompt diagnosis and management are required to improve their clinical outcomes. 
Various studies have shown statins to be effective in the cardiovascular risk reduction in patients 
with mild-to-moderate CKD as well as in renal transplant recipients. However, according to 
recent clinical randomized controlled trials (4D, A Study to Evaluate the Use of Rosuvastatin 
in Subjects on Regular Dialysis: an Assessment of Survival and Cardiovascular Events, and 
Study of Heart and Renal protection), these beneficial effects are uncertain in dialyzed patients. 
Therefore, further research for the most suitable treatment options is needed.
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Introduction
Chronic kidney disease (CKD) is one of today’s leading public health problems, with 
increasing frequency and prevalence. According to the Kidney Disease Outcomes 
Quality Initiative (K/DOQI), CKD is defined as kidney damage or a decreased kidney 
glomerular filtration rate (GFR) of <60 mL/min/1.73m2 for at least 3 months.1,2 Patients 
with CKD, particularly those with end-stage renal disease (ESRD) who are treated with 
hemodialysis (HD) or peritoneal dialysis (PD) or those treated with renal transplantation, 
are at increased risk of developing cardiovascular disease (CVD).3 It is more likely that 
patients with CKD will die because of CVD than develop ESRD and have the need for 
renal replacement therapy.3,4 Compared with the general population, patients with CKD 
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have an increased risk for developing CVD due to several risk 
factors often associated with CKD.5 These risk factors can 
be both traditional ones such as age, male gender, diabetes, 
obesity, hypertension, and dyslipidemia and non-traditional 
uremia-related risk factors such as anemia, hyperhomocyste-
inemia, mineral bone disease-CKD with hyperparathyroidism, 
oxidative stress, hypoalbuminemia, and chronic inflamma-
tion.3,4 In the general population, high total cholesterol (TC), 
high low-density lipoprotein (LDL) cholesterol, high triglyc-
eride, and low high-density lipoprotein (HDL) cholesterol 
are all well-established risk factors for CVD development. 
However, CKD, with both dialysis and transplantation, is 
associated with specific qualitative and quantitative lipid 
abnormalities, resulting in specific dyslipidemia (Table 1).1,3,6 
The relationship between dyslipidemia and CVD morbidity 
and mortality in this specific population group is not as clear 
as that in the general population.7 Specific abnormalities in the 
lipoprotein metabolism, caused by an inappropriate activity 
of some key enzymes and metabolic pathways, develop in the 
early stage of renal failure and result in dyslipidemia which 
presents a risk factor for the atherosclerosis development. 
Along with CKD progression, metabolic abnormalities may 
progress further, contributing to atherosclerotic changes and 
adversely affecting renal function.1,4,7 According to the current 
evidence, lipid-lowering medications are effective in reduc-
ing CVD mortality and morbidity in the general population. 
Recent studies suggest that these medications may have the 
same beneficial effect in both CKD and the transplant popu-
lation.3  This review presents the etiology and pathogenesis 
of specific lipid abnormalities in patients with CKD stage 
1–4 (G1–4), those with nephrotic syndrome, as well as those 
treated with dialysis and kidney transplantation and ends 
by summarizing the current evidence and guidelines for the 
management of dyslipidemia. 
Etiology and pathogenesis of 
dyslipidemia
Dyslipidemia in CKD (G1–4)
Dyslipidemia is a common complication of CKD and lipopro-
tein metabolism alteration and is associated with the decline 
in GFR; hence, lipid profile depends on the level of kidney 
function and the degree of proteinuria (Table 2).8,9 
Patients with non-dialysis-dependent CKD and without 
nephrotic syndrome have low HDL and high triglycerides 
and normal or even low TC and LDL cholesterol, but more 
atherogenic profile is hidden behind this spectrum. This pro-
file includes increased apolipoprotein B (apoB), lipoprotein 
(a) (Lp (a)), intermediate- and very-low-density lipoprotein 
(IDL cholesterol, VLDL cholesterol; “remnant particles”), 
and small dense LDL particles. Also, in patients with more 
severe CKD, LDL, and HDL particles are often modified by 
the oxidative process, that leads into the formation of small 
lipoproteins and increased formation of oxidized LDL.8,10,11
Patients with CKD usually have hypertriglyceridemia due 
to an increased concentration of triglyceride-rich lipoproteins 
(VLDL, chylomicrons, and their remnants). Hypertriglyc-
eridemia occurs because of both the delayed catabolism and 
the increased hepatic production of triglyceride-rich lipopro-
teins. Delayed catabolism is the most prevalent mechanism 
responsible for an elevated triglyceride-rich lipoprotein con-
centration in CKD patients and occurs probably because of a 
decreased activity of hepatic triglyceride lipase and peripheral 
lipoprotein lipase. Also, the presence of lipase inhibitors may 
contribute to delayed triglyceride-rich lipoprotein catabolism. 
Apolipoprotein C-III (apoC-III) is a direct lipoprotein lipase 
inhibitor, and its levels are elevated in uremia which further 
contributes to hypertriglyceridemia. It is also possible that 
secondary hyperparathyroidism plays an additional role in 
triglyceride-rich lipoprotein catabolism impairment, result-
ing in raised plasma triglyceride concentrations associated 
with CKD. Besides low catabolic activity, increased hepatic 
production of triglyceride-rich lipoproteins contributes to 
increased levels of triglycerides in CKD patients. Insulin 
resistance, often associated with CKD, seems to be respon-
sible for a hepatic VLDL overproduction.10,12
Table 1 Trend of changes in lipids, lipoproteins, and apoA-IV in 
various stages of CKD6
Parameter CKD 
1–5
Nephrotic 
syndrome
Hemodialysis Peritoneal 
dialysis
Total cholesterol ↗ ↑↑ ↔↓ ↑
LDL cholesterol ↗ ↑↑ ↔↓ ↑
HDL cholesterol ↓ ↓ ↓ ↓
Non-HDL 
cholesterol
↗ ↑↑ ↔↓ ↑
TG ↗ ↑↑ ↑ ↑
Lp (a) ↗ ↑↑ ↑ ↑↑
ApoA-I ↘ ↗ ↓ ↓
ApoA-IV ↗ ↑↘ ↑ ↑
ApoB ↗ ↑↑ ↔↓ ↑
Notes: Non-HDL cholesterol includes cholesterol in LDL, VLDL, IDL, and 
chylomicron and its remnant. Explanation of arrows: normal (↔), increased (↑), 
markedly increased (↑↑), and decreased (↓) plasma levels compared with non-
uremic individuals; increasing (↗) and decreasing (↘) plasma levels with decreasing 
GFR.  Copyright ©2007 American Society of Nephrology. Kwan BCH, Kronenberg F, 
Beddhu S, Cheung AK. Lipoprotein Metabolism and lipid management in chronic 
kidney disease. J Am Soc Nephrol. 2007;18:1246–1261.6
Abbreviations: apoA-IV, apolipoprotein A-IV; CKD, chronic kidney disease; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; Lp (a), 
lipoprotein(a); ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; VLDL, very-
low-density lipoprotein; IDL, intermediate-density lipoprotein; GFR, glomerular 
filtration rate.
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Although LDL is not usually elevated in patients with 
CKD, LDL particles tend to be smaller, denser, and more 
atherogenic in their form. Oxidized LDL and IDL, which are 
considered to be highly atherogenic, are increased. Various 
studies have shown increased levels of small dense LDL in 
non-dialysis-dependent CKD patients in comparison with the 
healthy controls and have indicated small dense LDL as a risk 
factor for CVD development. Because of the significantly 
modified lipid subfraction turnover, residence time of lipopro-
teins in the circulation is prolonged. Thus, lipoproteins are at 
risk of post-ribosomal modification which includes glycation, 
oxidation, and carbamylation. These modified lipoproteins 
have reduced affinity for the classic LDL receptors and are 
taken up by the scavenger receptors, increased in uremia, on 
the surface of the macrophages. High affinity for macrophages 
results in the accumulation of cholesterol and the formation 
of foam cells in the vascular walls, finally resulting in the 
development of accelerated atherosclerotic plaques.6,10,13
Lp (a) is an LDL-like lipoprotein which contains cova-
lently bounded apolipoprotein (a) (apo (a)) that distinguishes 
it from the LDL. Apo (a) is highly homologous to plasma 
protease zymogene plasminogen, and it is believed that it 
competes with plasminogen for binding to plasminogen 
receptors, fibrinogen, and fibrin. All these effects lead to 
promoted thrombogenesis by fibrinolysis inhibition. Recent 
evidences have shown that Lp (a) is highly associated with 
CVD incidence in the general population. Various studies, 
in both healthy individuals and CKD patients, have shown 
strong and negative association between apo (a) isoform size 
and the serum Lp (a) levels. Thus, serum Lp (a) levels depend 
on apo (a) isoform size and are highly genetically determined 
by the apo (a) gene. As mentioned earlier, individuals with 
predominantly low molecular weight apo (a) isoforms have 
on average, higher Lp (a) plasma concentrations. In patients 
with CKD, Lp (a) concentration is as well influenced by GFR; 
hence, patients with large apo (a) isoforms, and not those with 
small isoforms, tend to have increased Lp (a) levels early in 
CKD stage 1, even before GFR is significantly decreased. 
Finally, prospective studies have found small apo (a) isoform 
to be an even stronger predictor of total and cardiovascular 
mortality in CKD patients than total Lp (a) plasma level.3,6,12
Patients with CKD have decreased HDL in comparison 
with individuals with preserved kidney function. This state 
places them at higher risk for atherosclerosis development, 
especially considering the results of various epidemiological 
studies that presented HDL as a negative risk factor for ath-
erosclerosis. The main function of HDL is reverse cholesterol 
transport, a process that includes cholesterol transport from 
the arterial wall to the liver for further excretion. This together 
with HDL-mediated inhibition of inflammation, platelet 
adhesion, and LDL oxidation serves in normal circumstances 
against atherosclerosis, but in CKD patients, protective func-
tion of HDL is diminished because of several mechanisms. 
First, patients who have impaired kidney function often have 
decreased levels of apolipoproteins AI and AII, the main com-
ponents of HDL. Furthermore, in CKD patients, the activity 
of lecithin–cholesterol acyltransferase, the enzyme important 
for the esterification of free cholesterol in HDL, is impaired. 
On the other hand, the activity of cholesterol ester transfer 
protein (CETP), which supports the transfer of cholesterol 
esters from HDL to triglyceride-rich lipoproteins, is increased. 
All these processes are responsible for the decreased serum 
level of HDL. Besides its impaired function as the cholesterol 
carrier, patients with CKD have reduced activity of the HDL-
associated enzymes, such as paraoxonase, which may be 
responsible for impaired antioxidative and anti-inflammatory 
function of HDL. All these factors can contribute to acceler-
ated atherogenesis in this specific population.6,12,13 
Dyslipidemia in nephrotic syndrome 
There is an important difference in lipid profile between 
patients with and without nephrotic syndrome. In nephrotic 
Table 2 Lipid abnormalities by target population (approximate percentage)9
Total cholesterol 
>240 mg/dL
LDL cholesterol 
>130 mg/dL
HDL cholesterol 
<35 mg/dL
Triglyceride 
>200 mg/dL
General population* 20 40 15 15
CKD stages 1–4#
With nephrotic syndrome‡ 90 85 50 60
Without nephrotic syndrome‡ 30 10 35 40
CKD stage 5
Hemodialysis 20 30 50 45
Peritoneal dialysis 25 45 20 50
Notes: *Data from National Health and Nutrition Examination Survey III and the Framingham Offspring Study.32,33 #Data extracted from multiple observational studies of 
Kasiske.34 ‡Nephrotic proteinuria was defined as >3 g of total protein excretion in 24 h. Copyright ©2004 Society of General Internal Medicine. Weiner DE, Sarnak MJ. 
Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045–1052.9
Abbreviations: CKD, chronic kidney disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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syndrome, lipid profile is significantly atherogenic with 
increased TC and LDL, which is crucial for the diagnosis of 
nephrotic syndrome. In patients with CKD stage 1–4 with 
nephrotic syndrome, hypercholesterolemia occurs because 
LDL production is increased and catabolism is decreased. 
LDL clearance is slower because of the decreased function of 
hepatic LDL receptors. The mechanism of this insufficiency 
of receptor function is not completely known; however, stud-
ies on experimental animals have shown that an ineffective 
translation and/or an increased LDL-receptor protein turnover 
could be the main processes behind these changes. Also, an 
inverse correlation between serum albumin levels and TC 
and LDL levels is presented.8,10,12,14
Besides hypercholesterolemia, hypertriglyceridemia often 
occurs in nephrotic syndrome, and it seems to be caused 
mostly by the decreased catabolism of triglycerides. Delipida-
tion from triglyceride-rich lipoproteins, which is mediated by 
lipoprotein lipase and hepatic lipase, is impaired resulting in 
the accumulation of VLDL and remnant lipoproteins such as 
IDL. Impaired function of these enzymes may be caused by 
the loss of their activator cofactor in the urine. In addition, 
it seems that expression of these enzyme genes is downregu-
lated in patients with nephrotic syndrome.10,12
HDL levels are normal or even low in patients with 
nephrotic range proteinuria because of the mechanism 
similar to one described in the pathogenesis of the CKD 
without proteinuria.12 CKD patients with nephrotic range 
proteinuria have severely increased Lp (a) levels regardless 
of their apo (a) isoforms. This is probably due to heavy 
protein loss and consequent increased production of Lp 
(a) in the liver.10,12
Dyslipidemia in patients on dialysis 
HD
CKD patients who are on HD usually have similar lipid 
profile to those with non-dialysis-dependent CKD. TC and 
LDL levels are generally relatively normal, triglyceride lev-
els are elevated, and HDL is low. In these patients, LDL is 
rarely markedly elevated. However, the K/DOQI guideline 
on dyslipidemias in CKD patients has reported that 55.7% 
of patients on HD have LDL levels >100 mg/dL. These 
quantitative lipid abnormalities, as well as those qualitative 
hidden behind, play a role in atherosclerosis and cardiovas-
cular mortality in HD patients. Approximately 50% of ESRD 
patients die because of CVD, and cardiovascular mortality is 
30 times higher in dialysis patients.4,10,14 
HD patients have moderately increased apoB and signifi-
cantly increased apoC-III. Triglyceride-rich apoB  containing 
lipoproteins (VLDL and IDL) are elevated because of 
decreased activities of lipoprotein lipase and hepatic lipase, 
resulting in hypertriglyceridemia. The same mechanism 
occurs in non-dialysis-dependent CKD patients. Besides 
this mechanism, some factors related to the process of HD 
itself may contribute to the increase of triglyceride levels in 
HD patients. It is possible that low molecular weight heparin 
used for anticoagulation in this patients group may potentate 
triglyceride elevation. It is believed that heparin releases 
lipoprotein lipase from the endothelia surface; hence, its 
prolonged use may cause depletion in lipoprotein lipase and 
thus reduce triglyceride-rich lipoproteins catabolism. How-
ever, controversy surrounds the association between heparin 
use and HD-induced dyslipidemia because some studies have 
reported and others have not revealed any such association. 
Also, it is not so clear whether the type of the membrane 
used in HD has any influence on serum triglyceride levels. 
Some studies have shown the use of high flux polysulfone 
or cellulose triacetate membranes to be associated with a 
significant reduction in serum triglyceride levels. The reason 
for this reduction may be due to increased apoC-II/C-III 
ratio, resulting in increased lipoprotein lipase activity and 
improvement in lipolysis of the intravascular triglyceride-
rich lipoproteins.10,12
HD patients also have increased plasma Lp (a), which 
is isoform specific. Malnutrition and inflammation are usu-
ally present in this group of patients and together with the 
impaired clearance of apo (a) may be responsible for these 
alterations.12
In HD patients, HDL levels are reduced. A study of 183 
patients treated with HD15 without cholesterol medications 
has shown increased plasma levels of CETP in approximately 
one-third of the patients, which can be one of the factors 
responsible for these changes.10 In addition, HDL levels may 
be affected by the type of membrane or dialysate that is used 
in HD procedure. Thus, the use of high-flux membrane in 
comparison with low-flux membrane can increase HDL lev-
els. Also, the use of bicarbonate dialysate results in elevated 
HDL levels more often than the use of acetate dialysate.12
As mentioned earlier, behind the absence of hyperlip-
idemia, more atherogenic lipid profile in HD patients is 
usually presented. Shoji et al16 have compared 210 chronic 
HD patients and 223 age- and sex-matched healthy controls. 
The patients treated with HD had lower TC and higher tri-
glyceride than the controls. Also, HD patients had higher 
VLDL and IDL but lower HDL and LDL in comparison with 
the controls. Despite lower mean LDL levels, HD patients 
had significantly decreased cholesterol/triglyceride ratio, 
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 reflecting the domination of more atherogenic small dense 
LDL. Finally, other studies have also shown that HD patients 
have elevated Lp (a) and oxidized LDL forms even in cases 
in which LDL levels are mainly normal.10,17
Various clinical trials have shown reduction of LDL 
levels to be associated with CVD mortality reduction in the 
general population. However, it is obvious that in HD patients 
association between dyslipidemia and CVD mortality is not 
that simple as in the general population. Observational stud-
ies have noted the term “reverse epidemiology” between TC 
levels and risk of all-cause mortality. In other words, lower 
TC levels are associated with a higher mortality rate. Malnu-
trition/inflammation could be responsible for these observa-
tions.9,10 A retrospective study of 12,000 HD patients18 have 
shown that patients with low TC (<100 mg/dL [2.6 mmol/L]) 
had mortality risk more than 4 times higher in comparison 
with patients with TC levels. between 200 and 250 mg/dL 
(5.2–6.5 mmol/L). The association between TC and mortal-
ity formed a U-shaped curve that seemed more linear after 
adjustment for serum albumin.9,10 
One 10-year prospective study followed 1,167 Japanese 
HD patients.19 This study has shown low TC to be indepen-
dently associated with higher C-reactive protein (CRP) and 
mortality in patients with low albumin.10 Another prospec-
tive study followed 823 dialyzed patients for a median of 
2.4 years and classified them due to presence or absence of 
inflammation and/or malnutrition at baseline. Inflammation 
and/or malnutrition were defined by albumin serum levels, 
CRP or interleukin-6. An increase in baseline TC of 1 mmol/L 
was associated with a reduction of all-cause mortality in the 
presence of inflammation/malnutrition.10 
These studies results reveal that low serum TC levels are 
associated with increased mortality in HD patients, suggest-
ing hypocholesterolemia as a surrogate for malnutrition or 
inflammation.9,10
PD
Patients on PD have some form of “uremic dyslipidemia” just 
like those on HD, but their lipid profile is more atherogenic 
in nature with more altered dyslipidemia when compared 
with those on HD.3,10,12 PD patients show increased levels of 
triglyceride, apoB containing VLDL and IDL, TC and LDL, as 
well as small dense LDL and Lp (a) while HDL levels are low. 
These differences may be attributed to PD per se, but may also 
be associated with the selection of dialytic modality. One cross-
sectional study compared 31 patients on continuous ambula-
tory peritoneal dialysis (CAPD), 30 patients treated with HD, 
and 27 healthy controls. Patients on CAPD had significantly 
higher mean TC (6.8 vs 5.1 mmol/L, p<0.001),  LDL (4.6 vs 
3.2 mmol/L, p<0.001), VLDL (1 vs 0.7 mmol/L, p<0.05), and 
triglyceride (2.3 vs 1.5 mmol/L, p<0.01) than patients on HD. 
Also, there was no significant difference in HDL (1.1 vs 1.3 
mmol/L in HD, p=NS) in patients on CAPD.10
Hypertriglyceridemia is predominantly present in patients 
on PD. The exact mechanism is not completely understood, but 
it is believed that a significant absorption of glucose from the 
dialysis fluid may induce hepatic lipoprotein synthesis or may 
cause an increase in insulin levels resulting in the enhanced 
hepatic VLDL synthesis and secretion. Recent studies have 
shown an improvement in lipid profile when the overnight 
dwell has been switched from a dextrose-based solution to 
icodextrin, because of the reduced glucose overload.10,12
Higher TC, LDL and small dense LDL can be explained 
by several mechanisms similar to those in nephrotic syn-
drome and those related to the protein loss. In PD patients, 
great amounts of plasma proteins are lost into the peritoneal 
dialysate, which stimulates the liver to produce albumin and 
other proteins, including cholesterol-enriched lipoproteins in 
an attempt to compensate for the protein loss. Also, various 
lipoproteins, such as HDL, are lost through the peritoneal 
cavity which may contribute to its decreased levels.10,12
Compared to HD, patients on PD have increased Lp (a) 
plasma levels which are not isoform specific. Also, Lp (a) 
levels are usually more elevated in patients on PD than those 
on HD.10 This may be due to enhanced Lp (a) synthesis in 
the liver as a result of the increased protein loss.12 In their 
large multicenter cross-sectional study, Kronenberg et al17 
have shown that 34% of HD patients and 42% of CAPD 
patients had serum Lp (a) greater than the 75th percentile 
of the healthy control group (>0.92 mmol/L, p<0.005 for 
HD vs PD).10
Dyslipidemia in renal transplant patients
CVD is the most common cause of death in the renal trans-
plant population. These patients often die with a functional 
graft because of CVD, and thus, CVD is the most com-
mon cause of graft loss. Dyslipidemia is an important risk 
factor for CVD development, and its incidence in the 1st 
year following kidney transplantation can go beyond 50%. 
Lipid profile in renal transplant patients includes elevated 
plasma levels of TC, LDL, VLDL, and triglyceride while 
HDL is significantly reduced. Many factors can influence 
post-transplant dyslipidemia including age, genetic predis-
position, obesity and reduced physical activity, nephrotic 
syndrome, hypothyreosis, diabetes mellitus, chronic liver 
disease, and immunosuppressive agents. These medications 
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include calcineurin inhibitors (CNIs), primarily cyclospo-
rine, followed by corticosteroids and mTOR inhibitors.3,21–23 
Corticosteroids can induce dyslipidemia by the stimula-
tion of liver lipid synthesis, especially VLDL synthesis, as 
well as by decreasing LDL hepatic intake. Cyclosporine is 
responsible for the elevation of TC and LDL and reduction 
of HDL levels which is dose dependent. These changes in 
the lipid profile are caused by the binding of cyclosporine 
to hepatic LDL receptors and consequently disrupted liver 
LDL uptake. Tacrolimus, azathioprine, and mycophenolate 
mofetil usually cause minimal changes in the lipid profile; 
hence, the replacement of cyclosporine with one of these 
medications can improve serum triglyceride and cholesterol 
levels, but does not have any effect on HDL levels. mTOR 
inhibitor sirolimus significantly increases triglyceride 
plasma levels by inducing the synthesis and secretion of 
liver triglyceride and VLDL. When used in combination, 
sirolimus and cyclosporine synergistically contribute to the 
development of dyslipidemia in kidney transplant recipients. 
Finally, dyslipidemia in kidney transplant patients can have 
negative impact on kidney graft function which leads to the 
conclusion that lipid lowering could have beneficial effect 
on the graft function.3,21 
One recent retrospective case–control and before–after 
study has shown an improvement in the lipid profile after 
kidney transplantation when compared with ESRD. In this 
study, a retrospective case–control analysis of 816 patients 
admitted to the Royal Hobart Hospital in 2008–2009 with 
different degrees of kidney impairment and retrospective 
before–after cohort analysis of 60 patients who received 
a transplanted kidney between 1999 and 2009 was per-
formed. After kidney transplantation, HDL has significantly 
increased (p<0.0001) and triglyceride levels have sig-
nificantly decreased (p=0.007). TC and LDL levels haven’t 
significantly changed. HDL and triglycerides level improve-
ment following kidney transplantation was associated with 
successful engraftment and maintenance of graft function. 
If graft function was not successful, HDL again decreased 
and triglycerides levels increased. Some limitations of this 
study have to be considered, including immunosuppressive 
medications which could affect lipoprotein metabolism and 
concentration as well as a frequent statin use in the studied 
population which could affect TC and LDL levels after kid-
ney transplantation. But according to these results, it can be 
concluded that kidney function is an important determinant 
of HDL and triglyceride concentrations in CKD and kidney 
transplant patients which can affect CVD risk associated 
with CKD,24 
Management of dyslipidemia
From the previously described pathogenesis of dyslipidemia 
in patients with renal impairment, it is obvious that dys-
lipidemia accelerates atherogenic processes and increases 
CVD risk in this population. However, dyslipidemia can 
also worsen the decline in the kidney function because of 
deposition of lipids in the kidney. In 1982, Moorhead et al25 
investigated the association between hyperlipidemia and renal 
function impairment, and since then, various new evidences 
have supported this hypothesis. It is believed that deposition 
of lipid may cause damage to mesangial cells, endothelial 
cells, and glomerular podocytes by inducing inflammatory 
reaction and matrix production in glomerular mesangium, 
resulting in glomerulosclerosis. Lipid accumulation may, 
with time, increase loss of functioning of nephrons, resulting 
in worsening of the renal function.23
According to the potential negative effects of dyslipid-
emia on CVD development and impairment of renal func-
tion, it is logical to speculate that initiation of dyslipidemia 
controlling therapy in patients with renal impairment could 
mitigate its negative renal and cardiovascular consequences. 
However, evidences of these beneficial effects are still lack-
ing mostly because patients with CKD were often excluded 
from major trials that evaluated dyslipidemia treatment and 
its impact on CVD prevention. Clinical trials have confirmed 
that reduction of LDL leads to decreased cardiovascular 
mortality, but in the CKD population, this association is less 
clear. Some authors claim that dyslipidemia associated with 
renal impairment should be considered as a coronary heart 
disease-risk equivalent similar to diabetes mellitus and thus 
should be intensively treated.23,26
Management of dyslipidemia in CKD 
(G1–4)
Statins are medications that are very often prescribed for 
lipid lowering in the general population, and various large, 
randomized, prospective studies have shown that their use 
leads to significant decrease in cardiovascular events.6,12,23 In 
the uremic patients, statins are as effective in lowering the 
TC and LDL as they are in the general population, but their 
beneficial effect on cardiovascular morbidity and mortality 
in CKD patients seems to depend on the severity of renal 
dysfunction. Also, it should be mentioned that statins do 
not have an effect on hyperglyceridemia, elevated Lp (a) and 
decreased HDL levels which are often presented in CKD 
patients.12,23  Various studies have shown statins to be effective 
in the cardiovascular risk reduction. Some of these studies 
are the Treatment to New Targets (TNT), Heart  Protection 
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Study (HPS), combined analysis of the Cholesterol and 
Recurrent Events (CARE), West of Scotland Coronary Pre-
vention Study, and Long-term Intervention with Pravastatin 
in Ischemic Disease studies.23 
The HPS included 20,000 British men and women aged 
40–80 years who had an increased risk of CVD death because 
of diabetes, CVD, and other atherosclerotic diseases. The 
study was conducted for 5 years. The primary outcomes have 
been to evaluate total mortality, fatal and nonfatal vascular 
events after cholesterol lowering with 40 mg/day simvastatin. 
In this study, a subgroup of 1,329 CKD patients whose cre-
atinine ranged from 1.3 to 2.3 mg/dL have been enrolled. In 
this subgroup, relative risk (RR) reduction was 28% (95% 
confidence interval [CI] 0.72–0.85; p<0.05). Compared with 
the control group, the event rate has been reduced in the 
group that was receiving simvastatin (control group 39.2% 
vs simvastatin group 28.2%) and has resulted in the 11% 
absolute risk reduction.27 Similar results have been obtained 
in the Anglo-Scandinavian Cardiac Outcomes Trial in which 
a subgroup of 6,517 patients with kidney dysfunction have 
been analyzed after receiving 10 mg of atorvastatin per day 
during a median of 3.3 years follow-up. Atorvastatin has 
significantly reduced the risk for the primary composite 
end point of nonfatal myocardial infarction (MI) and fatal 
coronary heart disease by 39%.12 
In the CARE study, 4,159 patients with hyperlipidemia and 
history of acute MI were randomized to receive pravastatin or 
placebo. After a 5-year follow-up period, their cardiovascular 
morbidity and mortality have been evaluated. In the subgroup 
of 1,700 patients with mild CKD (creatinine clearance <75 
mL/min) receiving 40 mg pravastatin per day, there was a 28% 
(95% CI 0.55–0.95; p=0.02) RR reduction and a 4% absolute 
risk reduction in the primary end point that included death 
from coronary disease and symptomatic nonfatal MI.23,27
Some studies have shown statins to be renoprotective not 
just because of their ability to reduce lipid levels, but because 
of their ability to reduce interstitial inflammation, improve 
renal hemodynamics and decrease glomerular proteinuria 
which could result in the reduction of renal function decline. 
This was confirmed by the analysis of a subgroup of patients 
in the TNT study. Patients who have been receiving 80 mg 
of atorvastatin were compared with patients who have been 
receiving 10 mg of atorvastatin per day after a 5-year follow-
up period. An increase in GFR has been observed in both 
the groups of patients, but the increase was higher in the 80 
mg receiving group.13,23
According to the Kidney Disease: Improving Global Out-
comes (KDIGO) guidelines in adults with newly  identified 
CKD, evaluation of a lipid profile (TC, LDL, HDL, and 
triglycerides) should be performed mainly because of the 
potential severe hypercholesterolemia or hypertriglyceride-
mia diagnosis and potential secondary cause establishment. 
There is no precise evidence on usefulness of the measure-
ment of the lipid status and its potential to improve clinical 
outcomes, but the levels of triglyceride >11.3 mmol/L or 
LDL >4.9 mmol/L may require further evaluation. Thus, 
follow-up measurement of lipid levels in adults with CKD is 
not required for the majority of patients especially because 
clinical benefits of statin treatment are proportional to the 
baseline coronary risk rather than baseline LDL.28
Available evidence suggests absolute risk for coronary 
events as a deciding factor for receiving cholesterol-lowering 
medication in CKD patients instead of LDL levels measure-
ment. The size of the excess risk, which is associated with 
increased LDL levels, decreases when eGFR levels are low 
in non-dialysis dependent CKD patients.28
KDIGO guidelines recommend treatment with a statin 
or statin/ezetimibe combination in adults aged ≥50 years 
with eGFR <60 mL/min/1.73 m2 who are not treated with 
chronic dialysis or kidney transplantation (GFR categories 
G3a–G5).28
The Study of Heart and Renal Protection (SHARP), 
international double-blind randomized trial included 9,270 
CKD patients to receive simvastatin 20 mg plus ezetimibe 10 
mg daily or placebo during the mean 4.9 years of follow-up 
period. Most non-dialysis-dependent CKD patients (n=6,247) 
were in stages 3 and 4 (mean eGFR =27 mL/min/1.73 m2), and 
the remaining 3,023 patients were receiving dialysis (HD and 
PD). Combination of the simvastatin plus ezetimibe has led 
to the 0.83 mmol/L mean reduction in LDL in the  treatment 
group in comparison with the placebo. Combination therapy 
caused significant 17% RR reduction of the primary outcome 
of major atherosclerotic events (coronary death, MI, non-
hemorrhagic stroke, or any revascularization) compared with 
placebo (HR 0.83; 95% CI 0.74–0.94). However, the effect of 
treatment on coronary events (coronary heart disease death 
and nonfatal MI) was not different (p=0.37). In the 6,247 
non-dialysis-dependent CKD patients, simvastatin/ezetimibe 
therapy did not reduce the risk of progression to the ESRD. 
In the subgroup of dialysis-dependent patients treatment 
with simvastatin/ezetimibe combination did not significantly 
reduce the risk of the primary outcome.3,26,28
According to SHARP results, post hoc analyses of 
randomized trials from the general population, as well as 
those focusing on the subgroups with CKD, and KDIGO 
guidelines recommend such treatment in the previously 
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described patients with CKD because of their generally high 
cardiovascular risk.28
Finally, according to KDIGO guidelines, in adults aged 
18–49 years with CKD but not treated with chronic dialysis 
or kidney transplantation, statin treatment is recommended 
in the case of known coronary disease (MI or coronary 
revascularization), diabetes mellitus, prior ischemic stroke 
or estimated 10-year incidence of coronary death or non-
fatal MI >10%.28
In adults with CKD (including those treated with 
chronic dialysis or kidney transplantation), according to 
KDIGO guidelines, therapeutic lifestyle changes should 
be advised. Therapeutic lifestyle changes include dietary 
modification, weight reduction, increased physical activity, 
reducing alcohol intake, and treatment of hyperglycemia if 
present. Evidence shows that lifestyle changes can reduce 
serum triglyceride levels in CKD patients is weak but may 
improve general health. However, according to KDIGO 
guidelines, CKD patients with high fasting triglyceride 
serum levels (5.65 mmol/L or 500 mg/dL) should adopt a 
low-fat diet (<15% total calories), reduce monosaccharide 
and disaccharide intake as well as the total amount of dietary 
carbohydrates, and use fish oils to replace some long-chain 
triglycerides. Dietary changes should be performed very 
carefully in malnourished patients.28
Because of hypertriglyceridemia being presented in CKD 
patients, fibrates seem to be the logical treatment option for 
these patients. However, evidence from the randomized con-
trolled trials about potential protective effect of these medica-
tions is still lacking. Furthermore, these medications are not 
often used in practice because of the concern of rhabdomy-
olysis, worsening of the renal function, impairment of the 
liver function or development of elevation of  homocysteine 
in CKD patients.23 KDIGO guidelines  recommend fibric acid 
derivate to be used only in rare cases of markedly elevated 
fasting levels of serum triglycerides (11.3 mmol/L or 1,000 
mg/dL). In such cases, doses of fibric acid derivate have 
to be adjusted for kidney function and should not be used 
with statins because of potential toxicity. Taken together, 
fibric acid derivates are not recommended for prevention of 
 pancreatitis or reduce cardiovascular risk in CKD patients 
with hypertriglyceridemia.28
Management of dyslipidemia in nephrotic 
syndrome
Nephrotic-range proteinuria is usually associated with hyper-
cholesterolemia and hypertriglyceridemia. It is possible that 
reduction in proteinuria could improve dyslipidemia in these 
patients. However, evidence confirming this hypothesis is 
inconsistent. Only a few randomized controlled trials have 
demonstrated the association between therapies that can 
reduce the excretion of urine protein and beneficial effect on 
the lipid profile. Angiotensin II-converting enzyme inhibi-
tors (ACE-I), angiotensin II receptor blockers (ARBs), and 
diets with low protein intake often reduce the excretion of 
urine protein. One randomized controlled trial included 17 
nephrotic patients treated with an ACE-I. After the follow-
up period, the reduction in the excretion of urine protein 
and mean TC have been observed when compared with the 
placebo group. Evidence of the effect of low-protein diets 
on the lipid profile in nephrotic-range proteinuria patients is 
also lacking. Modification of Diet in Renal Disease study has 
reported a tendency of serum TC and LDL levels lowering 
with the reduction of dietary protein intake.29
It is well known that ACE-I and ARBs can decline the 
progression of the renal disease in patients with and without 
proteinuria. Thus, patients with CKD and proteinuria should 
be treated with ACE-I or ARBS despite the levels of plasma 
lipids.29
The majority of CKD patients with eGFR ≥60 mL/
min/1.73m2 have proteinuria.28 These patients are rarely recog-
nized in the randomized trials of statins. According to the cur-
rent evidence, the presence of albuminuria does not decrease 
the beneficial effects of the statin treatment. The CARD and 
CARE trials have not found any significant interaction between 
the presence of albuminuria and statin treatment effect on 
cardiovascular events. Considering the high cardiovascular 
risk in the CKD stages 1 and 2 patients and the evidence 
demonstrating statins to be equally effective in the presence 
or absence of proteinuria, KDIGO guidelines recommend that 
adults aged ≥50 years with CKD and eGFR ≥60 mL/min/1.73 
m2 (GFR categories G1–G2) should be treated with a statin.28
Management of dyslipidemia in patients 
on dialysis
HD and PD
It is well known that HD and PD patients are at high risk of 
CVD morbidity and mortality, but data about the association 
of lipid-lowering treatment and reduction of cardiovascular 
mortality in this population is conflicting. The majority of 
CV deaths in dialysis patients are caused by sudden death that 
may be because of electrolyte abnormalities or arrhythmia 
or cardiomyopathy that may be due to chronic extracellular 
fluid volume overload and not by the atherosclerotic coronary 
heart disease. Thus, it is possible that positive effects of statins 
on the atherosclerotic events may have been diluted. Some 
epidemiological studies have shown statins to be effective in 
cardiovascular mortality reduction. US Renal Data System 
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Dialysis Morbidity and Mortality Study included 3,700 
HD patients who were followed for 2 years. In the group of 
patients receiving statins, RR reduction in total mortality 
was 32% in comparison with the group of patients receiving 
fibrates that did not develop any reduction in cardiovascular 
or total mortality. Similar positive effects of statins on the 
relative reduction in total mortality have been shown in the 
Dialysis Outcomes Practice Patterns observational study. 
However, the prospective, randomized trials that have evalu-
ated the effects of the statin use in this patient population have 
not shown such positive results as epidemiological studies; 
their results seem to be disappointing.10,12,27 
The 4D Study (Die Deutsche Diabetes Dialyse Studie) is 
a multicenter, double-blind, randomized trial that included 
1,255 patients with type 2 diabetes treated with HD. They 
have been receiving maintenance HD for <2 years. Patients 
were randomized to receive atorvastatin 20 mg/day or placebo 
and followed up for 4 years. After 4 weeks, atorvastatin treat-
ment reduced the LDL levels by 42% in comparison with 
1.3% reduction in the placebo group. Despite this significant 
reduction in LDL levels, atorvastatin had a non-significant 8% 
RR reduction (95% CI 0.77–1.10; p=0.37) on the combined 
primary end point (a composite of cardiac death, nonfatal MI, 
and stroke). Moreover, atorvastatin increased the risk of fatal 
stoke in this patient population (RR 2.03; 95% CI 1.05–3.93; 
p=0.04). The secondary endpoint of combined cardiac events 
was significantly decreased (RR 0.82; 95% CI 0.68–0.99; 
p=0.03). However, not all combined cerebrovascular events 
and total mortality was significantly reduced.6,12,13,26–28
The A Study to Evaluate the Use of Rosuvastatin in Sub-
jects on Regular Dialysis: An Assessment of Survival and Car-
diovascular Events (AURORA) is an international prospective 
double-blind study that included 2,776 HD patients. They have 
been randomized to receive 10 mg of rosuvastatin per day or 
placebo. The primary combined end points were nonfatal MI, 
nonfatal stroke, and cardiovascular death. After a period of 
3 months, the reduction of LDL was 43% in the rosuvastatin 
group. Despite this significant reduction in LDL levels, the 
combined primary endpoint was not reduced after a median 
follow-up period of 3.8 years (HR 0.96; 95% CI 0.84–1.11; 
p=0.59). Furthermore, there was no reduction in the risk of the 
individual components of the primary endpoint or reduction 
in all-cause mortality ((HR 0.96; 95% CI 0.86–1.07; p=0.51). 
The results of the AURORA study may lead to the concept of 
“a point of no return”. In other words, there might be a point 
in the impairment of the renal function in which beneficial 
effects of a statin therapy are modified by the uremic envi-
ronment. Despite some of the limitations of these studies, as 
well as the previously described SHARP study, their results 
have caused a great amount of concerns about efficiency of 
the statin use in the dialyzed population.12,26,28 
Although dialyzed patients have high CVD risk, these 
data suggest that clinical benefits of statin or statin/ezetimibe 
treatment are uncertain. Thus, KDIGO guidelines do not rec-
ommend an initiation of statin or statin/ezetimibe treatment in 
most adult, dialysis-dependent CKD patients. Still, patients can 
use statins with the awareness of a relatively small and uncer-
tain CVD risk reduction. In patients who are already receiving 
statin or statin/ezetimibe therapy at the time of dialysis initia-
tion, according to KDIGO guidelines such therapy should be 
continued with a regular monitoring of the patients’ condition 
given the lack of evidence that could advise different approach.28
Management of dyslipidemia in renal 
transplant patients
Renal transplant recipients are considered to be at high risk 
for CVD development. Managing dyslipidemia through 
the lifestyle changes is often insufficient; hence, medica-
tions are often needed. Statins are the most commonly used 
medications in this patient group and are proved to be safe 
and effective, not only in the lipid profile improvement, but 
also in protecting graft function.22
The Assessment of Lescol in Renal Transplantation 
(ALERT) is a large, randomized, placebo-controlled trial 
designed to evaluate the effect of statin treatment on the 
cardiovascular risk reduction. The study included 2,102 
renal transplant recipients aged 30–75 years with functional 
allograft who were randomized to receive 40–80 mg/day 
fluvastatin therapy or placebo and followed up for 5–6 years. 
The fluvastatin therapy led to nonsignificant (17%) reduc-
tion in the primary outcome of coronary death or non-fatal 
MI in comparison to placebo (RR 0.83; 95% CI 0.64–1.06). 
However, the RR reduction in cardiac death or definite 
nonfatal MI caused by fluvastatin therapy was significant 
(35%) compared with placebo (HR 0.65; 95% CI 0.48–0.88). 
Importantly, unblended extension study showed significant 
decrease in the original primary outcome due to fluvastatin 
therapy after 6.7 years of follow-up. The lipid-lowering and 
cardiovascular benefits of fluvastatin therapy observed from 
the ALERT study are comparable with the beneficial effects 
of statin therapy in the general population. Thus, KDIGO 
guidelines suggest statin treatment in adult kidney transplant 
recipients.9,13,14,26,28 
When used in combination, cyclosporine can interact 
with some of the statins resulting in potential myopathy and 
rhabdomyolysis. Thus, in renal transplant recipients receiving 
a cyclosporine, a lower dose of statin should be used with 
more careful monitoring of these patients.14,22 
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Finally, various studies have shown ezetimibe to be 
effective when used with statins. In their retrospective 
review, Buchanan et al30 evaluated the safety and efficiency 
of ezetimibe in renal transplant patients. Monotherapy or 
combination therapy resulted in a mean reduction in TC of 
23.3%, triglycerides 40.2%, LDL 16.8%, and HDL 4.8% 
after 3.1 months of therapy. According to these results, 
ezetimibe is safe and effective for dyslipidemia treatment in 
renal transplant recipients, both as a combination or mono-
therapy. Also, ezetimibe does not change the CNI levels and 
renal function.30 Similar results have been observed by the 
study of Türk et al.31 
Conclusion
Dyslipidemia is often present in patients with renal impair-
ment and differs quantitatively and qualitatively in non-
dialyses-dependent patients, patients with nephrotic range 
proteinuria, ESRD patients, and renal transplant recipients. 
It can affect kidney function and significantly increase the 
risk of CVD development. Thus, diagnosis and management 
of these patients are important to potentially improve their 
clinical outcome. However, according to recent large clini-
cal trials, effects of treatment in reducing CVD morbidity 
and mortality in patients with renal impairment are not as 
promising as in general population. Thus, further research 
is needed to find the most beneficial treatment options for 
these patients. 
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